recent
year
dramat
increas
applic
plant
biotechnolog
product
varieti
commerci
valuabl
simpl
complex
biolog
molecul
biolog
use
human
anim
healthcar
transgen
whole
plant
plant
cell
cultur
system
develop
capac
econom
produc
largescal
quantiti
antibodi
antibodi
fragment
antigen
andor
vaccin
epitop
metabol
enzym
hormon
neuro
peptid
varieti
biolog
activ
complex
secondari
metabolit
direct
use
therapeut
agent
diagnost
tool
medic
healthcar
industri
product
genet
modifi
plant
make
way
concept
commerci
associ
risk
accept
public
becom
focal
point
paper
summar
recent
advanc
made
use
transgen
plant
plant
cell
cultur
biolog
factori
product
human
therapeut
biopharmaceut
discuss
longterm
potenti
molecular
farm
lowcost
effici
method
product
biolog
materi
demonstr
util
pharmaceut
industri
medic
commun
much
like
green
revolut
chang
agricultur
lead
dramat
improv
crop
yield
worldwid
advent
genet
engin
earli
applic
plant
biolog
revolution
agricultur
contribut
dramat
growth
biotechnolog
industri
plant
biotechnolog
boast
one
largest
share
total
biotechnolog
market
global
impact
agricultur
crop
product
food
qualiti
human
nutrit
health
develop
emerg
nation
two
import
discoveri
form
foundat
modern
plant
biotechnolog
togeth
enabl
plant
scientist
develop
new
procedur
crop
improv
base
genet
engin
first
discoveri
natur
gene
transfer
mechan
use
plantpathogen
bacterium
agrobacterium
tumefacien
introduc
genet
materi
plant
genom
infect
process
van
lerebek
et
al
second
breakthrough
capac
regener
whole
plant
singl
cell
without
chang
genet
featur
cell
birch
togeth
discoveri
enabl
numer
laboratori
worldwid
conduct
success
gene
transfer
plant
genom
gener
transgen
plant
stabl
express
introduc
foreign
gene
bevan
et
al
zambryski
et
al
sinc
time
plant
biotechnolog
becom
cornerston
expand
biotechnolog
revolut
wit
steadi
develop
new
techniqu
identif
isol
potenti
import
plant
gene
improv
method
manipul
transfer
gene
plant
cell
develop
better
techniqu
recoveri
transform
cell
regener
transgen
plant
et
al
paul
saxena
et
al
newel
verones
et
al
rakoczytrojanowska
main
object
creat
transgen
plant
use
new
power
approach
attempt
modifi
metabol
pathway
product
tailormad
low
molecular
weight
compound
polym
increas
resist
toward
biotic
abiot
stress
improv
food
qualiti
alter
carbohydr
protein
lipid
composit
product
polypeptid
medic
pharmaceut
industri
use
ap
ree
herber
sonnewald
miflin
ye
et
al
kumar
rohini
rao
verones
et
al
lessard
et
al
sharma
et
al
exploit
plant
biotechnolog
produc
diagnost
therapeut
product
becom
wellrecogn
import
field
biopharmaceut
scienc
promis
econom
potenti
although
major
focu
last
year
microbi
anim
cell
cultur
whole
plant
plant
cell
cultur
con
sider
viabl
competit
system
largescal
product
industri
pharmaceut
recombin
protein
secondari
metabolit
recent
variou
recombin
protein
express
plant
includ
antibodi
viral
bacteri
antigen
variou
human
anim
therapeut
protein
use
plant
genet
engin
advanc
tool
fischer
et
al
herber
sonnewald
doran
gid
et
al
daniel
et
al
larrick
thoma
korban
engin
transgen
plant
mani
potenti
advantag
product
recombin
protein
compar
microbi
anim
cell
cultur
system
transgen
anim
among
product
raw
materi
agricultur
scale
low
cost
possibl
case
use
edibl
plant
materi
directli
reduc
capit
cost
rel
ferment
method
rapid
scale
product
correct
eukaryot
assembl
multimer
protein
antibodi
unlik
bacteria
increas
safeti
sinc
plant
serv
host
human
pathogen
hiv
prion
hepat
virus
etc
ponstein
et
al
evangelista
et
al
timko
cahoon
langridg
gid
larrick
thoma
develop
new
plant
varieti
genet
engin
seen
progress
toward
environment
friendli
agricultur
less
relianc
costli
fertil
decreas
use
toxic
pesticid
herbicid
regard
plant
genet
manipul
often
accept
gener
public
genebas
experiment
involv
anim
gene
therapi
research
human
jorgensen
et
al
remain
howev
signific
portion
societi
less
accept
new
technolog
passion
argu
product
use
geneticallymodifi
organ
gmo
regardless
whether
plant
microb
anim
mani
among
sector
view
use
transgen
plant
transgen
plantderiv
product
first
step
toward
ecolog
destruct
among
concern
rais
oppon
gmo
gm
plant
particular
potenti
transgen
escap
contamin
natur
environ
increas
potenti
allerg
reaction
result
presenc
transgen
unexpect
modif
result
genet
manipul
lead
introduct
novel
plant
antigen
gener
uncertainti
regard
growth
test
plant
use
product
human
bioactiv
compound
would
monitor
purpos
review
outlin
recent
progress
made
use
transgen
plant
plant
cell
cultur
product
human
therapeut
relat
biolog
includ
antibodi
antibodi
fragment
pathogenderiv
protein
antigen
subunit
vaccin
epitop
hormoneand
neuropeptid
enzym
therapeut
nutrit
signific
secondari
metabolit
pharmacolog
properti
medicin
valu
attempt
discuss
recent
advanc
made
plant
genet
engin
rather
concentr
develop
bear
directli
progress
toward
use
plant
vehicl
produc
compound
valu
human
therapeut
four
major
area
research
address
product
peptid
protein
enzym
industri
pharmacolog
valu
gener
antibodi
antibodi
fragment
plant
transgen
plant
vaccin
product
system
manipul
plant
metabol
product
novel
compound
secondari
metabolit
medicin
valu
possibl
comment
known
econom
feasibl
approach
well
limit
risk
involv
inform
aspect
plant
genet
engin
relat
improv
agronom
trait
diseas
resist
food
qualiti
reader
refer
recent
review
comai
kahl
winter
goddijn
pen
collin
shepherd
antibodi
protein
molecul
form
b
lymphocyt
vertebr
immun
system
recogn
bind
specif
molecular
epitop
term
antigen
wide
varieti
substanc
serv
antigen
includ
protein
carbohydr
simpl
organ
molecul
even
metal
ion
compound
enter
bodi
may
carri
invad
organ
kilpatrick
et
al
role
antibodi
neutral
antigen
target
remov
cell
main
serum
immunoglobulin
antibodi
class
igg
iga
igm
igd
ige
igg
antibodi
among
common
type
antibodi
form
cell
follow
igm
iga
igg
antibodi
consist
two
pair
ident
polypeptid
term
heavi
light
chain
two
heavi
chain
join
area
littl
varianc
fc
region
form
two
light
chain
connect
arm
disulfid
bond
end
arm
contain
variabl
region
fv
molecul
respons
interact
particular
antigen
antibodi
molecul
made
two
ident
light
chain
heavi
chain
one
heavi
light
chain
combin
form
antigen
bind
site
immunoglobulin
monom
capabl
bind
two
antigen
molecul
secretori
antibodi
complex
structur
serum
counterpart
dimer
serumtyp
antibodi
two
monom
attach
addit
compon
call
join
chain
jchain
also
polypeptid
call
secretori
compon
protect
antibodi
proteas
constant
region
immunoglobulin
requir
antigen
recognit
possibl
express
smaller
deriv
still
retain
antigenbind
specif
chadd
chamow
fischer
et
al
fab
f
fragment
contain
sequenc
distal
hing
region
singl
chain
fv
fragment
scfv
contain
variabl
region
heavi
light
chain
join
flexibl
peptid
chain
often
effect
drug
fulllength
immunoglobulin
show
increas
penetr
target
tissu
reduc
immunogen
clear
tissu
rapidli
deriv
includ
bispecif
scfv
contain
antigen
recognit
element
two
differ
immunoglobulin
bind
two
differ
antigen
scfvfusion
link
protein
addit
function
fischer
et
al
recent
commerci
product
antibodi
primarili
accomplish
one
two
mean
first
method
involv
elicit
immun
respons
host
anim
follow
anim
sacrific
recoveri
antibodi
blood
serum
second
method
reli
use
anim
cell
cultur
either
case
amount
antibodi
recov
cost
purif
place
sever
limit
avail
materi
gene
encod
heavi
light
chain
polypeptid
isol
lymphocyt
becam
possibl
overexpress
molecul
transgen
organ
first
report
describ
success
express
antibodi
transgen
plant
occur
late
earli
hiatt
et
al
et
al
sinc
time
combin
two
rapidli
advanc
technolog
immunolog
plant
genet
engin
result
express
divers
rang
antibodi
often
refer
plantibodi
numer
vascular
plant
green
algal
speci
see
review
conrad
fiedler
kilpatrick
et
al
hein
timko
cahoon
fischer
eman
smith
glick
larrrick
thoma
stoger
et
al
base
publish
find
transgen
plant
andor
plant
cell
cultur
offer
number
advantag
product
antibodi
extract
human
anim
fluidstissu
use
recombin
microb
transfect
anim
cell
line
transgen
anim
advantag
includ
low
cost
product
eas
scale
meet
market
demand
lower
capit
cost
mammalian
cell
cultur
transgen
system
freedom
possibl
contamin
associ
bloodborn
interspecif
pathogen
addit
transgen
plant
system
allow
express
heavi
lightchain
assembl
function
dimer
antibodi
vivo
vitro
similar
mammalian
secretori
antibodi
hiatt
et
al
et
al
hein
et
al
de
neve
et
al
et
al
smith
glick
antigenbind
fragment
fab
singlechain
bind
fragment
scfv
function
full
size
antibodi
express
leav
seed
plant
without
loss
bind
specif
affin
hiatt
et
al
de
neve
et
al
et
al
baum
et
al
fischer
et
al
smith
glick
xu
et
al
sever
research
group
success
express
activ
fulllength
antibodi
plant
target
antibodi
apoplast
space
ie
space
adjac
plant
cell
via
endoplasm
reticulum
er
smith
glick
appear
apoplast
provid
environ
suitabl
accur
assembl
complex
molecul
gener
one
two
differ
approach
employ
produc
biolog
activ
whole
antibodi
plant
transform
heavi
lightchain
gene
separ
plant
follow
crosspollin
two
transgen
parent
yield
f
individu
carri
heavi
light
chain
gene
hiatt
et
al
hein
et
al
et
al
cotransform
heavi
light
chain
gene
singl
express
cassett
et
al
denev
et
al
voss
et
al
although
coexpress
heavi
light
chain
gene
singl
express
cassett
may
less
involv
see
et
al
denev
et
al
voss
et
al
use
crosspollin
strategi
also
possibl
produc
wide
rang
novel
antibodi
combin
plant
line
carri
differ
set
modif
either
heavi
light
chain
et
al
use
former
strategi
hiatt
cowork
hiatt
et
al
hiatt
report
success
product
igg
antibodi
plant
igg
antibodi
recogn
synthet
phosphon
ester
p
catalyz
hydrolysi
certain
carboxyl
ester
hiatt
cowork
constitut
express
igg
heavi
light
chain
gene
separ
tobacco
plant
crosspollin
transgen
parent
line
produc
f
progeni
coexpress
chain
major
f
progeni
express
gene
produc
assembl
fulllength
antibodi
product
f
line
express
fulllength
antibodi
total
solubl
protein
suspens
cell
cultur
deriv
f
transgen
progeni
secret
mg
l
antibodi
cultur
medium
hein
et
al
subsequ
et
al
report
express
complex
iga
secretori
antibodi
plant
secretori
iga
primari
form
antibodi
produc
mucos
secret
throughout
gastrointestin
tract
assembl
iga
complex
et
al
engin
four
transgen
tobacco
line
contain
differ
compon
iga
complex
cross
variou
combin
obtain
lg
recombin
iga
antibodi
per
gm
fresh
leaf
tissu
antibodi
function
indistinguish
antibodi
elicit
mous
abil
recogn
bind
antigen
hein
interestingli
synthesi
iga
antibodi
normal
requir
cooper
two
differ
mammalian
celltyp
ie
plasma
epitheli
cell
singl
transgen
tobacco
cell
abl
assembl
antibodi
without
requir
engin
assembl
factor
chaperonin
although
coexpress
heavi
lightchain
gene
singl
express
cassett
may
less
involv
use
crosspollin
strategi
also
possibl
produc
wide
rang
novel
antibodi
combin
plant
line
carri
differ
set
modif
either
heavi
light
chain
et
al
although
tobacco
leaf
popular
express
system
recombin
antibodi
sever
group
explor
use
plant
plant
seed
use
express
largescal
product
exampl
stoger
et
al
success
express
scfv
antibodi
carcinoembryon
antigen
cea
leav
grain
transgen
rice
wheat
gener
express
level
antibodi
less
wheat
rice
correspond
total
solubl
protein
comparison
express
crop
plant
less
optim
level
report
tobacco
conrad
fielder
transgen
field
pea
pisum
sativum
l
seed
also
use
product
antibodi
fragment
work
perrin
et
al
observ
level
express
lgg
tissu
compar
level
express
seen
plant
system
high
level
antibodi
product
could
also
achiev
transgen
potato
tuber
demonstr
artsaenko
et
al
biosynthesi
scfv
specif
bind
synthet
hapten
oxazolon
among
notabl
transgen
plant
system
use
antibodi
format
exploit
transgen
corn
seed
product
venu
recent
review
hood
et
al
corn
seed
shown
particular
util
product
high
level
secretori
immunoglobulin
siga
abund
antibodi
class
produc
bodi
total
immunoglobulin
secret
onto
mucos
surfac
provid
local
protect
toxin
pathogen
produc
recombin
siga
transgen
corn
seed
four
differ
gene
encod
four
protein
chain
siga
ie
humanaherp
lightchain
humanaherp
heavychain
human
jchain
human
secretori
compon
coexpress
gene
construct
code
region
gene
link
constitut
camv
promot
barley
aamylas
signal
sequenc
baass
direct
protein
cell
wall
matrix
use
express
scheme
recombin
siga
constitut
total
solubl
protein
singl
seed
achiev
base
upon
previou
studi
transgen
corn
demonstr
increas
recombin
protein
express
rang
follow
six
gener
recurr
select
backcross
hood
project
transgen
corn
seed
among
better
commerci
system
antibodi
express
short
period
time
product
recombin
plantderiv
antibodi
move
theori
phase
ii
clinic
trial
accord
pharmaceut
research
manufactur
america
see
http
wwwpharmaorg
recombin
antibodi
repres
singl
largest
group
biotechnologyderiv
molecul
clinic
trial
occupi
biopharmaceut
expect
reach
five
billion
dollar
prospect
market
like
due
fact
antibodi
larg
divers
potenti
applic
includ
use
medic
diagnosi
therapi
detect
remov
environment
contamin
control
pathogen
iv
industri
purif
process
among
product
signific
potenti
follow
carorx
tm
carorx
tm
antistreptococcu
mutan
secretori
immunoglobulin
siga
use
prevent
dental
cari
et
al
larrick
thoma
et
al
compar
monoclon
secretori
antibodi
gener
transgen
plant
parent
murin
igg
antibodi
report
affin
constant
antibodi
mutan
adhes
protein
similar
howev
secretori
antibodi
higher
function
affin
due
dimer
structur
human
oral
caviti
secretori
antibodi
surviv
three
day
compar
one
day
igg
antibodi
plant
secretori
antibodi
afford
specif
protect
human
oral
streptococc
colon
least
month
et
al
thu
initi
clinic
studi
carorx
tm
demonstr
topic
appli
anti
mutan
plantibodi
safe
ie
elicit
human
antimous
antibodi
respons
local
system
toxic
effect
ie
prevent
colon
mutan
major
caus
human
dental
cari
planet
biotechnolog
inc
complet
unit
state
food
drug
administr
fda
approv
phase
iii
confirmatori
clinic
trial
school
dentistri
univers
california
san
francisco
late
avicidin
fulllength
antibodi
specif
epcam
marker
colorect
cancer
develop
jointli
neorx
monsanto
avicidin
employ
mousederiv
antibodi
clinic
trial
treat
patient
solid
tumor
lung
prostat
colon
ovarian
cancer
longer
respond
standard
therapi
fischer
eman
although
tumor
shrinkag
occur
patient
number
dose
administ
limit
mousederiv
antibodi
known
caus
human
antimous
antibodi
patient
neorx
repres
first
time
protein
produc
plant
test
human
unfortun
phase
ii
trial
discontinu
exhibit
signific
gastrointestin
side
effect
fischer
eman
monoclon
antibodi
use
success
vivo
imag
diagnosi
human
colorect
carcinoma
william
et
al
recogn
carcinoembryon
antigen
cea
well
character
tumor
associ
glycoprotein
cea
detect
almost
human
colon
cancer
breast
cancer
tumor
epitheli
origin
vaquero
et
al
scfv
engin
antibodi
fragment
minibodi
bival
bind
cea
produc
genet
fusion
anticea
singlechain
antibodi
human
domain
hu
et
al
scfv
dimer
diabodi
construct
variabl
region
anticea
monoclon
antibodi
use
peptid
linker
eight
amino
acid
residu
diabodi
bound
antigen
bival
well
retain
high
appar
affin
cea
wu
et
al
full
length
igg
transient
express
tobacco
agroinfiltr
vaquero
et
al
scfv
express
transgen
tobacco
pea
rice
wheat
fischer
et
al
produc
diabodi
agroinfiltr
tobacco
vaquero
et
al
report
diabodi
fusion
transgen
tobacco
plant
antihsv
igg
recogn
herp
simplex
viru
zeitlin
et
al
express
human
antiherp
simplex
viru
monoclon
antibodi
soybean
compar
antibodi
express
mammalian
cell
cultur
report
similar
stabil
human
semen
cervic
mucu
h
abil
diffus
human
cervic
mucu
efficaci
prevent
vagin
infect
mous
topic
applic
recov
recombin
antibodi
shown
prevent
vagin
transmiss
mous
model
diseas
zeitlin
et
al
antiidiotyp
scfv
capabl
recogn
mous
lymphoma
cell
line
provid
immun
lethal
challeng
lymphoma
mccormick
et
al
mccormick
et
al
creat
modifi
tobamovir
vector
encod
idiotypespecif
singlechain
fv
fragment
immunoglobulin
infect
tobacco
plant
report
high
level
secret
scfv
protein
extracellular
compart
mice
protect
challeng
lethal
dose
syngen
tumor
similar
mice
immun
nativ
igmkeyhol
limpet
hemocyanin
conjug
vaccin
henc
rapid
product
system
gener
tumorspecif
protein
vaccin
may
provid
viabl
strategi
treatment
nonhodgkin
lymphoma
mccormick
et
al
hcg
synthes
secret
soon
fertil
tradit
use
index
pregnanc
bottger
et
al
hcg
circul
trophoblast
ovari
amen
inactiv
antibodi
sinc
immun
respons
vaccin
vari
greatli
individu
passiv
immun
use
antibodi
neutral
hcg
propos
contracept
measur
talwar
et
al
applic
antihcg
antibodi
diagnosi
prognosi
immunotherapi
cancer
okamoto
et
al
order
investig
efficaci
differ
antibodi
format
specif
hcg
kathuria
et
al
engin
chimer
fullsiz
igg
scfv
fragment
diabodi
deriv
origin
antihcg
murin
mab
pipp
express
tobacco
plant
recombin
antibodi
transient
produc
tobacco
leav
retain
specif
bhcg
hcg
antibodi
efficaci
confirm
vitro
inhibit
hcg
induc
product
testosteron
leydig
cell
block
hcg
induc
rise
mous
uterin
weight
vivo
studi
efficaci
shown
fullsiz
antihcg
antibodi
time
activ
either
scfv
fragment
diabodi
deriv
could
potenti
use
pregnanc
detect
emerg
contracept
diagnosi
andor
therapi
tumor
produc
hcg
kathuria
et
al
recent
avail
larg
amount
secretori
iga
plantibodi
also
open
number
novel
therapeut
opportun
disord
mucos
immun
system
includ
therapi
intestin
pathogen
helicobact
pylori
hepat
viru
enterotoxigen
e
coli
respiratori
pathogen
rhinoviru
influenza
larrick
thoma
genitourinari
sexual
transmit
diseas
eg
hsv
contracept
zeitlin
et
al
level
recombin
antibodi
rab
accumul
particular
plant
express
system
enhanc
use
appropri
regulatori
element
express
construct
optim
codon
usag
rab
gene
better
match
usag
plant
enhanc
stabil
antibodi
consider
also
exist
exampl
import
recogn
potenti
differ
activ
specif
might
exist
nativ
antibodi
recombin
antibodi
produc
anim
human
cell
plantbas
system
differ
could
aris
subtl
differ
antibodi
structur
caus
small
chang
secondari
modif
protein
modif
chang
glycosyl
pattern
plant
anim
cell
among
like
affect
antibodi
activ
reason
recent
effort
focus
human
plant
glycan
reduc
immunogen
potenti
cabanesmacheteau
et
al
analyz
glycosyl
function
mammalian
glycoprotein
express
transgen
plant
compar
nlink
glycan
attach
heavi
chain
guy
monoclon
antibodi
produc
transgen
tobacco
plant
igg
murin
origin
number
guy
glycoform
higher
plant
mammalian
express
antibodi
addit
highmannosetyp
nglycan
oligosaccharid
nlink
plantibodi
b
xylos
fucos
residu
link
core
linkag
found
mammalian
nlink
glycan
potenti
immunogen
thu
plantibodi
may
show
potenti
toxic
human
bakker
et
al
report
stabl
express
human
transferas
import
enzym
ie
miss
convers
typic
plant
nglycan
mammalianlik
nglycan
tobacco
plant
cross
tobacco
plant
express
human
transferas
plant
express
heavi
lightchain
mous
antibodi
result
express
plantibodi
exhibit
partial
galactosyl
nglycan
level
carbohydr
incorpor
approxim
abund
antibodi
produc
hybridoma
cell
result
repres
major
step
forward
engin
nglycosyl
recombin
protein
alter
glycan
structur
becom
essenti
aspect
antibodi
engin
anoth
option
creation
aglycosyl
antibodi
accomplish
alter
peptid
recognit
sequenc
nlink
glycosyl
asnxserthr
high
mannosetyp
glycosyl
may
favor
addit
ctermin
kdel
sequenc
subsequ
target
plantibodi
proxim
endoplasm
reticulum
kdel
sequenc
cleav
process
potenti
kdel
tag
alter
immunogen
pharmacokinet
properti
known
current
littl
inform
avail
effect
age
development
stage
physiolog
chang
yield
qualiti
foreign
protein
produc
plant
steven
et
al
show
level
antibodi
mous
heterolog
express
tobacco
parallel
total
solubl
protein
level
ratio
heterolog
leaf
total
solubl
protein
constant
throughout
develop
leaf
case
total
solubl
protein
content
decreas
plant
begin
senesc
senesc
enzymat
process
activ
major
protein
show
increas
turnov
rate
smart
buchananwollaston
proteolyt
degrad
major
part
senesc
process
begin
plant
tissu
reach
matur
proteolyt
degrad
seriou
obstacl
product
antibodi
planta
neg
affect
product
homogen
regul
environment
condit
moder
affect
heterolog
protein
express
exampl
decreas
growth
temperatur
alter
time
antibodi
turnoverdeclin
indirectli
control
rate
plant
develop
accumul
antibodi
matur
leaf
tissu
slightli
upregul
increas
light
level
reflect
gener
increas
leaf
total
solubl
protein
content
higher
irradi
steven
et
al
recent
signific
progress
made
recombin
antibodi
product
tobacco
corn
crop
particularli
express
seed
assur
excel
storag
properti
anoth
advantag
limit
rang
protein
seed
ad
flexibl
process
stoger
et
al
commerci
scale
product
recombin
antibodi
plant
also
benefit
food
beverag
industri
technolog
major
hurdl
purif
antibodi
plant
sort
easili
major
concern
phenol
alter
properti
protein
dramat
irrevers
remov
ultrafiltr
diafiltr
concern
includ
secondari
metabolit
endotoxin
mycotoxin
minim
rapid
process
earli
filtrat
remov
constitu
import
aspect
progress
toward
clinic
trial
plantibodi
realli
major
hurdl
sever
antibodi
purifi
homogen
human
clinic
use
plant
offer
number
attract
tradit
pharmaceut
manufactur
product
simpl
complex
therapeut
protein
develop
transform
cell
line
product
recombin
protein
rang
g
mammalian
cell
cultur
system
requir
month
morrow
scaleup
level
protein
product
requir
consider
time
larg
capit
invest
mani
case
cost
significantli
less
grow
plant
abil
massproduc
therapeuticpharmaceuticallyimport
protein
plantbas
express
system
like
associ
level
capit
invest
plantbas
product
scheme
also
easili
expand
contract
provid
quantiti
product
reflect
demand
depend
gener
time
one
harvest
transgen
plant
produc
target
recombin
protein
achiev
within
singl
grow
season
moreov
plant
seed
renew
resourc
quickli
scale
meet
need
cline
director
govern
industri
affair
monsanto
protein
technolog
estim
anim
cell
cultur
manufactur
facil
design
produc
kg
mab
per
year
type
singl
product
facil
current
use
pharmaceut
industri
would
requir
million
dollar
capit
would
take
year
build
approv
contrast
product
could
grown
acr
corn
purifi
facil
cost
million
requir
three
five
year
build
approv
cost
per
gram
mab
tradit
mean
per
gram
depend
scale
corn
would
cost
per
gram
depend
scale
similarli
suggest
gram
quantiti
recombin
antibodi
produc
tobacco
cell
cultur
transgen
plant
leaf
materi
month
scaleup
kilogram
less
year
among
product
benefit
simplifi
downstream
process
compar
tradit
product
technolog
abil
transgen
plant
accommod
wide
rang
protein
type
includ
possibl
tradit
product
technolog
enhanc
safeti
latter
factor
extrem
import
sinc
transgen
plant
express
system
provid
known
risk
transmiss
spongiform
encephalopathi
prion
known
transmiss
plant
virus
human
current
novel
antibodybas
potenti
product
clinic
trial
worldwid
market
demand
certainli
strain
capabl
exist
product
system
stoger
et
al
summari
plantbas
system
rab
product
highli
competit
term
product
safeti
cost
timelin
humphrey
glover
vaccin
consist
antigen
substanc
protein
peptid
attenu
live
kill
organ
capabl
elicit
immun
respons
preclud
infect
diseas
manifest
upon
later
challeng
pathogen
organ
vaccin
accomplish
introduc
antigen
parenter
bodi
bloodstream
thu
elicit
serum
immun
respons
oral
ingest
antigen
elicit
mucos
immun
respons
part
vaccin
reli
upon
serum
respons
although
good
exampl
success
oral
vaccin
ie
vaccin
polio
viru
comparison
parenter
immun
effici
sinc
oral
immun
appear
requir
consider
larg
amount
subunit
solubl
antigen
mg
versu
lg
amount
elicit
respons
de
aizpurua
russelljon
reason
present
time
consider
interest
exploit
abil
overexpress
antigen
protein
human
diseasecaus
agent
transgen
plant
use
vaccin
product
immun
inject
parenter
deliveri
rare
result
specif
protect
immun
respons
mucos
surfac
respiratori
gastrointestin
genitourinari
tract
mani
pathogen
enter
bodi
nose
mouth
open
therefor
mucos
immun
respons
repres
first
line
defens
biggest
pathogendet
surfac
bodi
mucos
immun
respons
effect
stimul
gener
molecul
known
secretori
antibodi
iga
dash
caviti
passageway
neutral
pathogen
find
effect
reaction
also
activ
system
respons
circul
cell
immun
system
help
destroy
invad
distant
site
addit
mucos
vaccin
deliv
oral
increas
safeti
complianc
elimin
need
needl
subunit
vaccin
effect
current
depend
capitalintens
fermentationbas
technolog
cold
chain
refriger
deliveri
factor
creat
constraint
use
develop
world
vaccin
need
idea
transgen
plantderiv
vaccin
origin
earli
time
charl
arntzen
colleagu
envisag
costeffect
vaccin
product
system
safe
efficaci
deliveri
system
use
plant
specif
engin
deliv
safe
subunit
prepar
candid
antigen
major
diseas
afflict
develop
develop
nation
walmsley
arntzen
scenario
antigen
could
produc
palat
plant
organ
ie
fruit
tuber
seed
allow
eaten
directli
therebi
immun
sidestep
demand
purif
numer
associ
product
storag
refriger
cost
cost
time
personnel
deliveryadministr
vaccin
langridg
walmsley
arntzen
addit
transgen
plant
could
potenti
use
produc
kg
amount
antigen
utiliz
tradit
parenter
oral
vaccin
prepar
first
demonstr
vaccin
antigen
express
report
ri
curtiss
ca
cardineau
express
streptococcu
mutan
surfac
protein
antigen
spaa
tobacco
curtiss
cardineau
feed
transgen
tobacco
tissu
mice
research
observ
mucos
immun
respons
induc
respons
spaa
protein
although
mice
subsequ
test
protect
direct
challeng
pathogen
induc
antibodi
demonstr
biolog
activ
react
intact
mutan
subsequ
c
arntzen
collabor
provid
proof
concept
refer
edibl
vaccin
show
surfac
antigen
hepat
b
could
synthes
transgen
plant
anim
fed
transgen
plant
materi
contain
immunogen
protein
develop
specif
immun
respons
recombin
antigen
mason
et
al
mason
sinc
initi
report
numer
plant
speci
use
antigen
express
includ
tobacco
potato
tomato
banana
corn
lupin
lettuc
walmsley
arntzen
carter
langridg
sala
et
al
list
protect
antigen
microbi
viral
pathogen
express
plant
becom
increasingli
larger
attent
spread
human
pathogen
anim
pathogen
tabl
develop
edibl
oral
vaccin
certainli
among
excit
current
research
area
review
see
mason
arntzen
featherston
thanavala
sala
et
al
transgen
express
candid
vaccin
antigen
accomplish
primarili
two
way
use
stabl
plant
transform
transient
gene
express
stabl
integr
recombin
dna
nuclear
chloroplast
genom
plant
cell
follow
regener
transform
plant
result
product
genet
line
propag
either
veget
mean
eg
stem
root
cut
sexual
reproduct
seed
product
foreign
gene
integr
nuclear
genom
inherit
express
typic
mendelian
fashion
wherea
express
chloroplast
show
matern
pattern
inherit
agrobacterium
tumefaciensbas
gene
transfer
common
way
research
introduc
sequenc
encod
vaccin
antigen
aziz
et
al
epitop
plant
nuclear
genom
sever
laboratori
also
develop
chloroplast
transform
express
system
vaccin
antigen
express
daniel
et
al
ruf
et
al
success
improv
level
gene
express
observ
nuclear
transform
daniel
et
al
daniel
et
al
altern
stabl
gene
integr
number
research
group
demonstr
specif
modifi
recombin
plant
virus
use
vector
transient
express
foreign
gene
encod
protein
plant
cell
beachi
et
al
modelska
et
al
nemchinov
et
al
koprowski
yushibov
mor
et
al
rational
studi
base
notion
viral
replic
gene
copi
number
becom
amplifi
result
much
higher
level
transgen
express
observ
stabl
transform
among
potenti
advantag
transient
viral
express
transgen
stabli
transform
transgen
plant
shorter
time
clone
foreign
gene
viral
genom
compar
time
requir
transform
plant
eas
antigen
product
scale
wide
host
rang
plant
virus
allow
use
multipl
plant
speci
biofactori
koprowski
yushibov
present
time
prospect
develop
effect
edibl
vaccin
oral
immun
without
limit
express
level
obtain
thu
far
transgen
plant
optimum
need
enhanc
addit
vaccin
candid
protein
highli
immunogen
plant
tissu
secondari
metabolit
found
plant
may
compromis
abil
vaccin
candid
protein
induc
immun
exampl
discuss
commonli
show
plant
accumul
foreign
protein
rel
low
level
total
solubl
protein
less
immunogen
protein
would
requir
even
larger
dose
effect
even
palat
altern
potato
eg
banana
accumul
level
limit
practic
edibl
vaccin
two
solut
overcom
limit
explor
first
techniqu
enhanc
antigen
accumul
plant
tissu
explor
number
factor
includ
codon
usag
natur
transcript
regulatori
sequenc
promot
use
type
sequenc
incorpor
presenc
specif
intraand
extracellular
target
compartment
sequenc
present
site
gene
integr
genom
etc
affect
transgen
express
ultim
vaccin
epitop
accumul
plant
optim
code
sequenc
bacteri
viral
gene
transient
express
well
defin
best
subcellular
compart
product
accumul
obtain
optim
quantiti
qualiti
also
consid
enhanc
immunogen
oral
deliv
antigen
use
carrier
protein
may
also
requir
especi
small
nonparticul
subunit
vaccin
antigen
walmsley
arntzen
anoth
approach
use
bacteri
enterotoxin
ct
lt
mammalian
viral
immunomodul
plantderiv
secondari
metabolit
yu
langridg
clearli
addit
experiment
area
need
human
trial
edibl
plant
vaccin
current
underway
hepat
b
bacteri
norwalk
virusinduc
diarrhea
statu
work
describ
decad
pass
sinc
mason
et
al
report
success
express
hepat
b
antigen
hbsag
tobacco
first
time
although
level
express
low
approxim
total
solubl
protein
plantexpress
antigen
form
viru
like
particl
vlp
similar
appear
form
commerci
avail
vaccin
rombovax
produc
yeast
merck
sharp
dohm
elicit
immunogen
respons
thanavala
et
al
variou
research
report
use
vlp
nonliv
vaccin
express
plant
lauterslag
et
al
preliminari
human
trial
tacket
et
al
kong
et
al
subsequ
hbsag
express
potato
arntzen
et
al
richter
et
al
banana
may
et
al
lettuc
kapusta
et
al
follow
initi
clinic
trial
kapusta
et
al
report
oral
deliveri
hbsag
stimul
develop
antihbsag
igg
human
subsequ
clinic
trial
perform
roswel
park
cancer
institut
buffalo
ny
patient
previous
vaccin
yeast
recombin
inject
hbsag
fed
raw
potato
express
hbsag
show
stimul
antibodi
titr
base
promis
preliminari
result
trial
continu
forward
mason
et
al
arakawa
et
al
b
engin
transgen
potato
produc
part
labil
toxin
b
ltb
secret
e
coli
bacterium
cholera
toxin
b
ctb
secret
vibrio
cholera
bacterium
respect
organ
caus
diarrhea
secret
toxin
bind
specif
gangliosid
present
epitheli
cell
surfac
recombin
ltb
ctb
produc
transgen
potato
show
antibodi
respons
ingest
mice
prove
plantproduc
protein
fold
correctli
assembl
nativ
bind
pentamer
complex
arakawa
et
al
b
mason
et
al
human
trial
phase
proofofconcept
trial
perform
healthi
adult
chosen
random
receiv
genet
engin
potato
three
receiv
piec
ordinari
potato
investig
analyz
blood
stool
sampl
volunt
evalu
vaccin
abil
stimul
system
intestin
immun
respons
ten
eleven
volunt
ingest
transgen
potato
fourfold
increas
serum
antibodi
point
immun
six
eleven
volunt
develop
four
fold
increas
intestin
antibodi
potato
well
toler
one
experienc
seriou
advers
side
effect
norwalk
viru
capsid
protein
nvcp
diarrhea
caus
norwalk
viru
express
transgen
tobacco
potato
total
solubl
protein
also
assembl
vlp
stimul
serum
igg
gut
iga
specif
nvcp
fed
mice
mason
et
al
clinic
trial
conduct
center
vaccin
develop
nvcp
potato
tacket
et
al
twenti
adult
ingest
either
two
three
dose
g
raw
potato
contain
lg
nvcp
nineteen
twenti
adult
show
signific
increas
number
specif
antinvcp
antibodysecret
cell
iga
subtyp
six
develop
increas
igg
antibodysecret
cell
studi
prove
oral
deliv
plantexpress
vlp
could
stimul
immun
respons
bind
activ
requir
oral
immun
potenti
applic
edibl
vaccin
includ
therapi
use
autoantigen
bodi
protein
recogn
foreign
immun
system
autoimmun
diseas
includ
arthriti
myasthenia
gravi
multipl
sclerosi
type
diabet
jevnikar
express
glutam
acid
dehydrogenas
potato
fed
nonobes
diabet
mice
reduc
pancreat
islet
inflamm
suggest
immunotoler
cytotox
tcellmedi
autoimmun
diseas
usual
appropri
oral
dose
plantderiv
auto
antigen
inhibit
develop
autoimmun
diseas
carter
langridg
sala
et
al
edibl
vaccin
develop
prevent
treatment
cancer
difficult
sinc
tumor
antigen
also
autoantigen
zhang
et
al
recent
polyepitop
isol
human
melanoma
tumor
integr
nuclear
chloroplast
dna
tobacco
attempt
develop
plantderiv
melanoma
vaccin
sala
et
al
mccormick
et
al
express
scfv
antibodi
fragment
immunoglobulin
mous
bcell
lymphoma
tobacco
viral
vector
show
mice
inject
vaccin
protect
challeng
lethal
dose
tumor
anoth
scfv
fuse
potato
viru
x
coat
protein
gener
protect
lymphoma
myeloma
savelyeva
et
al
addit
plantderiv
antibodi
edibl
vaccin
variou
pharmaceut
import
peptid
protein
enzym
produc
transgen
plant
offer
numer
biolog
econom
advantag
compar
industri
system
ie
extract
human
fluid
tissu
recombin
microorgan
microbi
ferment
transgen
anim
anim
cell
cultur
cramer
et
al
timko
cahoon
gid
exampl
cost
produc
larg
number
recombin
protein
plant
gener
larg
amount
biomass
start
point
protein
enzym
purif
rel
inexpens
compar
cost
larg
scale
microbi
ferment
anim
cell
cultur
unlik
mani
organ
plant
cell
quit
amen
accept
express
genet
inform
wide
rang
organ
includ
gene
prokaryot
eukaryot
sourc
walden
wingend
past
decad
larg
number
laboratori
report
success
express
varieti
heterolog
gene
plant
cell
capabl
exhibit
proper
tempor
spatial
regul
either
stabl
integr
nuclear
organellar
genom
transient
express
importantli
gene
transfer
method
properli
defin
transcript
translat
control
signal
level
transgen
express
heterolog
protein
biosynthesi
fall
well
within
rang
necessari
industri
scale
product
might
expect
express
level
vari
among
introduc
gene
result
number
factor
mention
earlier
review
transgen
plant
also
advantag
genet
engin
microorgan
product
protein
abl
produc
mammalian
protein
contain
appropri
posttransl
modif
eg
glycosyl
prenyl
format
sulfhydryl
bridg
often
necessari
proper
protein
enzym
function
howev
problem
notabl
among
proper
glycosyl
advers
affect
protein
function
potenti
problem
like
overcom
learn
requir
process
plant
anim
cell
bakker
et
al
anoth
concern
potenti
contamin
plantderiv
recombin
protein
potenti
toxic
factor
due
fact
plant
speci
contain
numer
toxic
alkaloid
secondari
metabolit
care
select
appropri
plant
materi
heterolog
express
help
allevi
potenti
problem
final
one
overlook
fact
genet
engin
plant
rais
ethic
issu
within
public
use
transgen
anim
experiment
research
industri
product
note
plant
genet
engin
like
aspect
gene
research
biotechnolog
propon
detractor
new
advanc
time
care
scrutini
cost
benefit
determin
whether
widespread
use
public
approv
gain
plant
test
rang
therapeut
protein
use
either
directli
food
purif
express
milk
protein
lactoferrin
bcasein
plant
may
contribut
therapeut
valu
protein
food
product
arakawa
et
al
chong
langridg
earlier
vandekerckhov
et
al
report
success
heterolog
express
leuenkephalin
painkil
neuropeptid
plant
fuse
part
brassica
napu
seed
storag
protein
recent
staub
et
al
report
product
correctli
process
human
somatotrophin
hst
transgen
tobacco
plant
express
level
chloroplast
total
solubl
protein
daniel
et
al
report
correctli
fold
hst
total
solubl
protein
choloroplast
growth
hormon
st
use
treatment
hypopituitari
dwarfism
children
possibl
futur
use
treat
turner
syndrom
chronic
renal
failur
hiv
wast
syndrom
staub
et
al
interest
plastidencod
protein
known
disulphid
bond
previous
establish
whether
chloroplast
could
correctli
process
protein
requir
disulphid
bond
biolog
activ
although
hst
one
first
protein
avail
recombin
e
coli
transgen
plant
advantag
abl
produc
somatotrophin
need
postextract
chemic
process
anoth
recent
exampl
adenosin
deaminas
ada
product
demonstr
transgen
maiz
part
develop
select
marker
system
possibl
use
treatment
adadefici
sever
combin
immunodefici
disord
petolino
et
al
protein
potenti
therapeut
applic
express
purif
plant
list
tabl
photoautotroph
plant
almost
unlimit
capac
growth
develop
along
inher
capac
unlimit
growth
plant
also
possess
rel
plastic
metabol
allow
rapidli
adapt
chang
environment
factor
pathogen
biotic
abiot
challeng
plastic
plant
metabol
activ
evid
wide
varieti
secondari
metabolit
accumul
plant
leav
root
organ
despit
fact
biosynthet
origin
role
plant
poorli
understood
consider
interest
potenti
industri
pharmacolog
medicin
valu
use
whole
plant
prepar
plant
extract
medicin
purpos
extend
well
record
histori
within
recent
time
mani
plantderiv
product
treat
human
disord
reach
market
place
use
drug
includ
atropin
hyoscyamin
scopolamin
taxol
anticanc
vinblastinevincristin
anticanc
artemisinin
antimalari
reserpin
antihypertens
quinin
antimalaria
abil
genet
engin
plant
genom
allow
direct
manipul
plant
metabol
potenti
manipul
content
natur
plant
secondari
metabolit
commerci
valu
plant
consid
potenti
factori
product
varieti
use
compound
kishor
somervil
ap
ree
kahl
winter
plant
cell
produc
far
chemic
compound
necessari
meet
basic
function
ie
growth
differenti
reproduct
larg
basic
primari
metabol
share
cell
secondari
metabol
gener
divers
seemingli
less
essenti
nonessenti
byproduct
call
secondari
metabolit
give
plant
variou
color
flavor
smell
product
sourc
fine
chemic
insecticid
dye
flavor
fragranc
drug
phytomedicin
found
medicin
plant
secondari
plant
product
play
essenti
role
medicin
thousand
year
repres
tremend
resourc
scientif
clinic
research
new
drug
develop
pharmacolog
valu
increas
due
constant
discoveri
potenti
role
healthcar
lead
chemic
new
drug
develop
despit
terashima
et
al
fact
biosynthet
origin
role
plant
poorli
understood
consider
interest
potenti
applic
tabl
genet
engin
secondari
metabol
pathway
aim
either
increas
decreas
quantiti
certain
compound
group
compound
verpoort
memelink
decreas
product
certain
unwant
group
compound
sever
approach
possibl
enzymat
step
pathway
knock
exampl
reduc
level
correspond
mrna
via
antisens
cosuppress
rna
interfer
rnai
technolog
express
antibodi
enzym
mahmoud
croteau
report
improv
qualiti
essenti
oil
express
antisens
deriv
methanofuran
synthas
gene
downregul
synthesi
undesir
constitu
methanofuran
mint
plant
approach
employ
product
novel
compound
plant
includ
metabolit
divers
competit
altern
pathway
increas
catabol
target
compound
chang
express
one
gene
overcom
specif
rate
limit
step
specif
pathway
transfer
part
metabol
pathway
organ
plant
success
endeavor
mix
attempt
modifi
terpenoid
metabol
gene
encod
xylulos
phosphat
synthas
dxp
first
enzymat
step
terpenoid
biosynthesi
constitut
overexpress
arabidopsi
increas
gene
express
coupl
increas
enzym
activ
correl
increas
accumul
plant
terpenoid
indic
dxp
rate
limit
estevez
et
al
similarli
muir
et
al
report
increas
flavonoid
level
tomato
fruit
overexpress
petunia
chalcon
isomeras
chi
gene
flavonoid
anthocyanin
known
antioxid
human
health
benefit
key
target
genet
improv
anoth
exampl
verpoort
memelink
show
one
could
specif
alter
alkaloid
level
catharnthu
roseu
cell
cultur
alter
express
gene
encod
tryptophan
decarboxylas
tdc
strictosidin
synthas
str
overexpress
tdc
result
podophyllum
peltatum
l
antineoplast
higher
level
immedi
product
tryptamin
affect
total
alkaloid
level
wherea
overexpress
str
led
increas
total
alkaloid
content
higher
level
alkaloid
note
canel
et
al
contrast
overexpress
transcript
regulatori
factor
control
sever
step
alkaloid
biosynthet
pathway
c
roseu
result
increas
alkaloid
product
van
der
fit
memelink
earli
success
geneexpress
base
strategi
coupl
increas
applic
proteom
metabolom
strategi
understand
secondari
metabol
control
bode
well
futur
manipul
plant
genom
product
wide
varieti
secondari
compound
antivir
bacteri
fungal
activ
human
therapeut
valu
within
short
time
span
use
genet
modifi
plant
product
therapeut
compound
move
experiment
system
signific
potenti
commerci
viabl
process
pois
deliv
product
use
anim
human
therapi
inroad
made
tradit
area
therapeut
develop
eg
identif
isol
bioactiv
secondari
metabolit
also
rel
unchart
area
product
novel
bioactiv
peptid
protein
antibodi
product
passiv
immun
therapi
edibl
oral
vaccin
rapid
pace
develop
wit
thu
far
like
acceler
near
futur
addit
novel
use
transgen
plant
product
system
human
therapeut
explor
limit
use
genet
modifi
plant
like
aris
still
somewhat
unsophist
knowledg
plant
gene
express
control
variou
metabol
pathway
within
plant
interact
regul
use
plant
product
factori
alreadi
seen
econom
attract
altern
product
compound
level
understand
factor
impact
transgen
express
plant
improv
see
improv
level
product
target
molecul
peptid
protein
antibodi
decreas
cost
product
greater
overal
exploit
plant
base
product
system
use
plantderiv
recombin
molecul
human
therapeut
agent
like
reach
fruition
without
address
regulatori
issu
surround
use
recombin
molecul
name
safeti
risk
versu
public
benefit
close
cooper
necessari
expert
medic
plant
engin
commun
address
potenti
concern
puriti
safeti
plantderiv
therapeut
demonstr
reliabl
costeffect
rel
convent
approach
would
unfair
gener
upon
limit
number
product
use
fact
recombin
plant
plant
product
alreadi
commerci
avail
indic
part
public
view
technolog
favor
public
accept
initi
product
associ
fact
case
clearli
provid
environment
friendli
altern
ie
decreas
use
herbicid
pesticid
current
agricultur
practic
whether
also
true
product
associ
human
therapeut
yet
determin
